Answers are grounded in this paper and cite their sources.
Supports destination therapy LVAD expansion in advanced HF; leaves open need for randomized confirmation outside Japan.
tality rates >40%. 1 Intravenous inotropes and durable left ventricular assist devices (LVAD) as bridge-to-transplan-D espite advancements in both medical treatment and interventional therapeutics for heart failure (HF), many patients still progress into an advanced phase.The prognosis of medically treated patients with advanced HF remains poor, with 1-year mor-Article p ????The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2026) conducted an editorial in Advanced heart failure. Durable left ventricular assist device (LVAD) implantation (since 2019 / Destination Therapy) vs. LVAD implantation up to 2018 / Bridge-to-transplantation (BTT) was evaluated on 4-year overall survival rate in destination therapy (DT) patients.
Synapse has enriched 10 related papers. Consider them for comparative context: